A Phase 3 interventional study of Tirzepatide and Semaglutide in Obesity and Overweight, sponsored by Eli Lilly and Company. Completed at 32 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-26.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies testing tirzepatide in Obesity — 60 open to participants now, 79 under way, 14 of them phase 3. Tirzepatide · Obesity.
Among the 104 studies testing tirzepatide in Obesity, this one is the 9th largest by enrollment, is one of 8 that started in 2023, is one of 26 in phase 3, and was the 13th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →60 of the 104 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
McMaster University · Sites in Canada
Ages 18–60
M.D. Anderson Cancer Center · Sites in United States
Ages 18–39
Eli Lilly and Company · Sites in United States, Belgium, Israel and 7 more countries
Ages 6–11
Eli Lilly and Company · Sites in United States
Ages 18–70
Columbia University · Sites in United States
Ages 40+
By country, each count listing its studies:
Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, tirzepatide is the treatment under test here. Read study by study →
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 24 · Phase 3 28 · Phase 4 29
First in 2019; this study’s year is marked. 8 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 751 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 69 across the 104 interventional studies. Of the 23 that completed or were terminated, 14 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 104 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
118 studies in Obesity by Eli Lilly and Company: 31 open now, 55 under way, 30 of them phase 3. Of 61 finished, 29 (48%) have results posted.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 26th largest by enrollment of the 117 interventional ones that give a count, is one of 21 that started in 2023, is one of 51 in phase 3, and was the 20th registered.
Eli Lilly and Company’s Obesity studies by the year they started, since 2009.
34 of the studies testing tirzepatide in Obesity that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07481747Phase 3Hudson BiotechEfficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | 2027-02-14 |
| NCT07738276Phase 3Shahid Beheshti University of Medical SciencesEvaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity | 2027-06-11 |
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
Add all 34 to your calendar (.ics) → With an account.
Among the 104 studies testing tirzepatide in Obesity, from their registry updates:
Among Eli Lilly and Company’s 118 in Obesity:
This tab as a report to print or save as PDF → With an account.
The main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide in adult participants who have obesity or overweight with weight related comorbidities without Type 2 Diabetes. The study will last around 74 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a starting dose of 2.5 milligrams (mg) tirzepatide administered subcutaneously (SC) once weekly (QW) for 4 weeks, then the dose was increased by 2.5 mg every 4 weeks (2.5 to 5 to 7.5 to 10 to 12.5 to 15 mg) up to 15 mg QW or maximum tolerated dose \[MTD (10 mg or 15 mg)\] until Week 72.
Drug: Tirzepatide
Participants received a starting dose of 0.25 mg semaglutide administered SC QW for 4 weeks, then the dose was increased every 4 weeks (0.25 to 0.5 to 1.0 to 1.7 to 2.4 mg) up to 2.4 mg QW or MTD (1.7 mg or 2.4 mg) until Week 72.
Drug: Semaglutide
Administered SC
Also known as: LY3298176
Administered SC
Percent Change From Baseline in Body Weight
Percent change from baseline in body weight was reported. Least Squares (LS) mean was determined using ANCOVA model with Baseline + Baseline BMI Group 1 + Sex + Pre diabetes status at randomization + Treatment (Type III sum of squares) as variables.
Time frame: Baseline, Week 72
Percentage of Participants Who Achieve ≥10% Body Weight Reduction
Percentage of participants who achieved ≥10% body weight reduction (observed values) was reported.
Time frame: Week 72
Percentage of Participants Who Achieve ≥15% Body Weight Reduction
Percentage of participants who achieved ≥15% body weight reduction (observed values) was reported.
Time frame: Week 72
Percentage of Participants Who Achieve ≥20% Body Weight Reduction
Percentage of participants who achieved ≥20% body weight reduction (observed values) was reported.
Time frame: Week 72
Percentage of Participants Who Achieve ≥25% Body Weight Reduction
Percentage of participants who achieved ≥25% body weight reduction (observed values) was reported.
Time frame: Week 72
Change From Baseline in Waist Circumference in Centimeter
Change from baseline in waist circumference in centimeter was reported. LS mean was determined using ANCOVA model with Baseline + Baseline BMI Group 1 + Sex + Pre diabetes status at randomization + Treatment (Type III sum of squares) as variables.
Time frame: Baseline, Week 72
Percentage of Participants Who Achieve ≥30% Body Weight Reduction
Percentage of participants who achieved ≥30% body weight reduction (observed values) was reported.
Time frame: Week 72
Change From Baseline in Body Mass Index (BMI)
Change from baseline in BMI was reported. LS mean was determined using Mixed Model Repeated Measures (MMRM) model using Baseline + Sex + Pre diabetes status at randomization + Treatment + Time + Treatment\*Time(Type III sum of squares) as variables.
Time frame: Baseline, Week 72
Percent Change From Baseline in Body Weight Comparing 15 mg Tirzepatide and 2.4 mg Semaglutide
Percent change from baseline in body weight comparing 15mg of Tirzepatide and 2.4 mg Semaglutide was reported. The treatment effect for tirzepatide versus semaglutide for percent change in body weight was also evaluated assuming that participants had stayed on treatment and reached the highest dose of treatment. LS mean was determined by MMRM model using Baseline + Sex + Pre diabetes status at randomization + Baseline BMI Group 1 + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 72
| Milestone | 15 mg or MTD - Tirzepatide | 2.4 mg or MTD - Semaglutide |
|---|---|---|
| Started | 375 | 376 |
| Received at least one dose of study drug | 374 | 376 |
| Completed | 319 | 319 |
| Not completed | 56 | 57 |
| Withdrew: Adverse event | 6 | 6 |
| Withdrew: Assigned treatment by mistake | 5 | 3 |
| Withdrew: Lost to follow-up | 16 | 18 |
| Withdrew: Non-compliance with study drug | 1 | 1 |
| Withdrew: Participant was out of the country | 0 | 1 |
| Withdrew: Pregnancy | 1 | 2 |
| Withdrew: Withdrawal by subject | 27 | 26 |
Percent change from baseline in body weight was reported. Least Squares (LS) mean was determined using ANCOVA model with Baseline + Baseline BMI Group 1 + Sex + Pre diabetes status at randomization + Treatment (Type III sum of squares) as variables.
| Percent change | 15 mg or MTD - Tirzepatide | 2.4 mg or MTD - Semaglutide |
|---|---|---|
| Percent Change From Baseline in Body Weight | -20.2 ± 0.59 | -13.7 ± 0.59 |
Percentage of participants who achieved ≥10% body weight reduction (observed values) was reported.
| Percentage of participants | 15 mg or MTD - Tirzepatide | 2.4 mg or MTD - Semaglutide |
|---|---|---|
| Percentage of Participants Who Achieve ≥10% Body Weight Reduction | 87.7 | 66.7 |
Percentage of participants who achieved ≥15% body weight reduction (observed values) was reported.
| Percentage of participants | 15 mg or MTD - Tirzepatide | 2.4 mg or MTD - Semaglutide |
|---|---|---|
| Percentage of Participants Who Achieve ≥15% Body Weight Reduction | 71.7 | 45.0 |
Percentage of participants who achieved ≥20% body weight reduction (observed values) was reported.
| Percentage of participants | 15 mg or MTD - Tirzepatide | 2.4 mg or MTD - Semaglutide |
|---|---|---|
| Percentage of Participants Who Achieve ≥20% Body Weight Reduction | 55.0 | 31.1 |
Percentage of participants who achieved ≥25% body weight reduction (observed values) was reported.
| Percentage of participants | 15 mg or MTD - Tirzepatide | 2.4 mg or MTD - Semaglutide |
|---|---|---|
| Percentage of Participants Who Achieve ≥25% Body Weight Reduction | 36.5 | 18.6 |
Change from baseline in waist circumference in centimeter was reported. LS mean was determined using ANCOVA model with Baseline + Baseline BMI Group 1 + Sex + Pre diabetes status at randomization + Treatment (Type III sum of squares) as variables.
| centimeters | 15 mg or MTD - Tirzepatide | 2.4 mg or MTD - Semaglutide |
|---|---|---|
| Change From Baseline in Waist Circumference in Centimeter | -18.4 ± 0.61 | -13.0 ± 0.66 |
Percentage of participants who achieved ≥30% body weight reduction (observed values) was reported.
| Percentage of participants | 15 mg or MTD - Tirzepatide | 2.4 mg or MTD - Semaglutide |
|---|---|---|
| Percentage of Participants Who Achieve ≥30% Body Weight Reduction | 23.0 | 8.2 |
Change from baseline in BMI was reported. LS mean was determined using Mixed Model Repeated Measures (MMRM) model using Baseline + Sex + Pre diabetes status at randomization + Treatment + Time + Treatment\*Time(Type III sum of squares) as variables.
| kilograms per meter square | 15 mg or MTD - Tirzepatide | 2.4 mg or MTD - Semaglutide |
|---|---|---|
| Change From Baseline in Body Mass Index (BMI) | -8.5 ± 0.24 | -6.0 ± 0.24 |
Percent change from baseline in body weight comparing 15mg of Tirzepatide and 2.4 mg Semaglutide was reported. The treatment effect for tirzepatide versus semaglutide for percent change in body weight was also evaluated assuming that participants had stayed on treatment and reached the highest dose of treatment. LS mean was determined by MMRM model using Baseline + Sex + Pre diabetes status at randomization + Baseline BMI Group 1 + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| Percent change | 15 mg or MTD - Tirzepatide | 2.4 mg or MTD - Semaglutide |
|---|---|---|
| Percent Change From Baseline in Body Weight Comparing 15 mg Tirzepatide and 2.4 mg Semaglutide | -21.8 ± 0.60 | -15.4 ± 0.60 |
Collected over Baseline Up To 72 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 15 mg or MTD - Tirzepatide | 0/374 (0%) | 18/374 (4.8%) | 255/374 (68.2%) |
| 2.4 mg or MTD - Semaglutide | 0/376 (0%) | 13/376 (3.5%) | 267/376 (71%) |
| Event | 15 mg or MTD - Tirzepatide | 2.4 mg or MTD - Semaglutide |
|---|---|---|
| CholelithiasisHepatobiliary disorders | 2/374 | 3/376 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/374 | 0/376 |
| Bile duct stoneHepatobiliary disorders | 0/374 | 2/376 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/242 | 1/243 |
| Atrial fibrillationCardiac disorders | 1/374 | 0/376 |
| Sinus tachycardiaCardiac disorders | 1/374 | 0/376 |
| Incarcerated hiatus herniaGastrointestinal disorders | 1/374 | 0/376 |
| VolvulusGastrointestinal disorders | 1/374 | 0/376 |
| CholecystitisHepatobiliary disorders | 1/374 | 0/376 |
| Cholecystitis acuteHepatobiliary disorders | 1/374 | 0/376 |
| Event | 15 mg or MTD - Tirzepatide | 2.4 mg or MTD - Semaglutide |
|---|---|---|
| NauseaGastrointestinal disorders | 163/374 | 167/376 |
| ConstipationGastrointestinal disorders | 101/374 | 107/376 |
| DiarrhoeaGastrointestinal disorders | 88/374 | 88/376 |
| VomitingGastrointestinal disorders | 56/374 | 80/376 |
| Covid-19Infections and infestations | 51/374 | 47/376 |
| FatigueGeneral disorders | 39/374 | 46/376 |
| Upper respiratory tract infectionInfections and infestations | 32/374 | 43/376 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 23/374 | 40/376 |
| EructationGastrointestinal disorders | 37/374 | 29/376 |
| Injection site reactionGeneral disorders | 32/374 | 1/376 |
All randomized participants who received at least one dose of study drug.
| Age, Continuous(years) | 15 mg or MTD - Tirzepatide | 2.4 mg or MTD - Semaglutide | Total |
|---|---|---|---|
| Mean | 45.00 ± 12.94 | 44.40 ± 12.74 | 44.70 ± 12.84 |
| Sex: Female, Male(Participants) | 15 mg or MTD - Tirzepatide | 2.4 mg or MTD - Semaglutide | Total |
|---|---|---|---|
| Female | 242 | 243 | 485 |
| Male | 132 | 133 | 265 |
| Ethnicity (NIH/OMB)(Participants) | 15 mg or MTD - Tirzepatide | 2.4 mg or MTD - Semaglutide | Total |
|---|---|---|---|
| Hispanic or Latino | 93 | 103 | 196 |
| Not Hispanic or Latino | 281 | 273 | 554 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 15 mg or MTD - Tirzepatide | 2.4 mg or MTD - Semaglutide | Total |
|---|---|---|---|
| American Indian or Alaska Native | 6 | 0 | 6 |
| Asian | 11 | 7 | 18 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 77 | 67 | 144 |
| White | 276 | 295 | 571 |
| More than one race | 4 | 7 | 11 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | 15 mg or MTD - Tirzepatide | 2.4 mg or MTD - Semaglutide | Total |
|---|---|---|---|
| United States | 374 | 376 | 750 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Apr 2023 to primary completion in Nov 2024, 18 months.
Results were first posted in Nov 2025, 1 year after primary completion.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 18 months is below that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide